PHARMACOLOGY PUBLICATIONS

  1. Celli B, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg CJ and Church A. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest 2014 Jan 2. doi: 10.1378/chest.13-1579. [Epub ahead of print]
  2. Leech KA, Kinnaird CR and Hornby TG. Effects of serotonergic medications on locomotor performance in humans with incomplete spinal cord injury. Journal of Neurotrauma 2014 Apr 17. [Epub ahead of print]
  3. Tong Chu VW, Hornby TG and Schmit BD. Effect of antispastic drugs on motor reflexes and voluntary muscle contraction in incomplete spinal cord injury. Archives of Physical Medicine and Rehabilitation 2014;95(4):622-32.
  4. Thompson CK and Hornby TG. Divergent modulation of clinical measures of volitional and reflexive motor behaviors following serotonergic medication in human incomplete spinal cord injury. Journal of Neurotrauma 2013;30(6):498-502.
  5. Hebert PL, McBean AM, O-Conner, H, Frank B, Good C and Maciejewski M. Time until incident dementia among Medicare beneficiaries using centrally acting or non-centrally acting ACE inhibitors. Pharmacoepidemiology and Drug Safety 2013;22(6):641-8.
  6. Hornby, TG, Kinnaird, CK, Holleran CL, Echauz A and Rodriguez KA. Serotonergic agents facilitate locomotor recovery in individuals post-stroke only when paired with locomotor training. Combined Sections Meeting for the American Physical Therapy Association, 2012.
  7. Tashkin DP, Celli BR, Decramer M, Lystig T, Liu D and Kesten S. Efficacy of tiotropium in COPD patients with FEV> 60% participating in the UPLIFT trial. COPD 2012;9:289-96.
  8. Cooper CB, Anzueto A, Decramer M, Celli B, Tashkin DP, Leimer I and Kesten S. Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials. International Journal of Chronic Obstructive Pulmonary Disease 2011;6:269-75.
  9. Fukuchi Y, Fernandez L, Kuo HP, Mahayiddin A, Celli B, Decramer M, Kesten S, Liu D and Tashkin D. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial. Respirology 2011;16: 825-35.
  10. Celli BR, Tashkin DP, Rennard SI, McElhattan J and Martin UJ. Bronchodilators responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine 2011;105:1523-30.
  11. Maltais F, Celli B, Casaburi R, Porszasz J, Jarreta D, Seoane B and Caracta C. Aclidinium bromide improves exercise endurance, dyspnea and capacity in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine 2011;105(4):580-7.
  12. Thompson CK, Jayaraman A, Kinnaird CR and Hornby TG. Methods to quantify pharmacologically induced alterations in motor function in human incomplete SCI. Journal of Visualized Experiments 2011;(50). pii:2148.
  13. Theiss RD, Hornby TG, Rymer WZ and Schmit BD. Riluzole decreases flexion withdrawal reflex but not voluntary ankle torque in human chronic spinal cord injury. Journal of Neurophysiology 2011;105(6):2781-90.
  14. Brookhart MA, Solomon DH, Glynn RJ and Ridker PM. Effect of rosuvastatin on hemoglobin levels in patients with anemia and low-grade inflammation: a post hoc analysis of the JUPITER Trial. Journal of Clinical Pharmacology 2011;51(10):1483-7.
  15. Hurst D, Loeffler G and McLay R. Psychosis associated with synthetic cannabinoid agonists: a case series. American Journal of Psychiatry 2011;168(10):1119.
  16. Phung OJ, Kahn SR, Cook DJ and Murad MH. Dosing frequency of unfractionated heparin thromboprophylaxis: a meta-analysis. Chest 2011;140(2):374-81.
  17. Winkelmayer WC, Stedman MR, Pogantsch M, Wieninger P, Bucsics A, Asslaber M, Bauer R, Burkhardt T, Schautzer A and Brookhart MA; Pharmacoeconomics Advisory Council of the Main Association of Austrian Sickness Funds. Guideline-conformity of initiation with oral hypoglycemic treatment for patients with newly therapy-dependent type 2 diabetes mellitus in Austria. Pharmacoepidemiology and Drug Safety 2011;20(1):57-65.
  18. Bounthavong M and Hsu DI. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis. Current Medical Research and Opinion 2010;26(2):407-41.
  19. Brookhart MA, Rassen JA and Schneeweiss S. Instrumental variable methods in comparative safety and effectiveness research. Pharmacoepidemiology and Drug Safety 2010;19(6):537-54.
  20. Kesselheim AS, Stedman MR, Bubrick EJ, Gagne JJ, Misono AS, Lee JL, Brookhart MA, Avorn J and Shrank WH. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs 2010;26;70(5):605-21.
  21. Patrick AR, Brookhart MA, Losina E, Schousboe JT, Cadarette SM, Mogun H and Solomon DH. The complex relation between bisphosphonate adherence and fracture reduction. Journal of Clinical Endocrinology & Metabolism 2010;95(7):3251-9.
  22. Phung OJ, Coleman CI, Baker EL, Scholle JM, Girotto JE, Makanji SS, Chen WT, Talati R, Kluger J, Quercia R, Mather J, Giovenale S and White CM. Effectiveness of recombinant human growth hormone (rhGH) in the treatment of patients with cystic fibrosis. Rockville, MD: Agency for Healthcare Research and Quality 2010 Oct; Report No.: 11-EHC003-EF.
  23. Thompson CK, Jayaraman A and Hornby TG. Modulation of supramaximal volitional torques and spastic reflexes following pharmacological manipulation of serotonin in human incomplete spinal cord injury. Combined Sections Meeting for the American Physical Therapy Association, 2010.
  24. Morice AH, Celli B, Kesten S, Lystig T, Tashkin D and Decramer M. COPD in young patients: A pre-specified analysis of the four-year trial of tiotropium (UPLIFT). Respiratory Medicine 2010;104(11):1659-67.
  25. Tashkin D, Celli B, Kesten S, Lystig T and Decramer M. Effect of tiotropium in men and women with COPD: Results of the 4-year UPLIFT trial. Respiratory Medicine. 2010;104(10):1495-504.
  26. Celli B, Decramer M, Leimer I, Vogel U, Kesten S and Tashkin DP. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010;137(1):20-30.
  27. Tashkin DP, Celli B, Kesten S, Lystig T, Mehra S and Decramer M. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. European Respiratory Journal 2010;35(2):287-94.
  28. Celli B, Decramer M, Kesten S, Liu D, Mehra S and Tashkin DP; UPLIFT Study Investigators. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2009;180(10):948-55.
  29. Decramer M, Celli B, Kesten S, Lystig T, Mehra S and Tashkin DP; UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): A prespecified subgroup analysis of a randomised controlled trial. The Lancet 2009;374:1171-8.
  30. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, Yates JC, Willits LR and Vestbo J. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respiratory Research 2009;10:59.
  31. Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Willits LR, Yates JC and Vestbo J. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal 2009;34(3):641-7.
  32. Thompson CK, Jayaraman A and Hornby TG. Serotonergic modulation of peak volitional torques and motoneuron excitability in human incomplete spinal cord injury. Society for Neuroscience, Chicago, IL, 2009:176.1.
  33. Hornby TG, Kahn JH, Moore JL, Kinnaird C and Echauz A. Combined selective serotonin reuptake inhibitors and locomotor training improves treadmill walking vs locomotor training alone in individuals with motor incomplete spinal cord injury. Society for Neuroscience, Chicago, IL, 2009:176.3.
  34. Bradbury BD, Do TP, Winkelmayer WC, Critchlow CW and Brookhart MA. Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL. Pharmacoepidemiology and Drug Safety 2009;18(10):932-40.
  35. Cadarette SM, Katz JN, Brookhart MA, Stürmer T, Stedman MR, Levin R and Solomon DH. Comparative gastrointestinal safety of weekly oral bisphosphonates. Osteoporosis International 2009;20(10):1735-47.
  36. Phung OJ, Baker WL, White CM and Coleman CI. Focus on clevidipine: an intravenous dihydropyridine calcium channel blocker for the treatment of acute hypertension. Formulary 2009;44:102-7.
  37. Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Rothman KJ, Fischer M, Mehta J and Winkelmayer WC. The effect of altitude on dosing and response to erythropoietin in ESRD. Journal of the American Society of Nephrology 2008;19(7):1389-95.
  38. Bowry AD, Brookhart MA and Choudhry NK. Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. American Journal of Cardiology 2008;101(7):960-6.
  39. Cadarette SM, Katz JN, Brookhart MA, Sturmer T, Stedman MR and Solomon DH. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Annals of Internal Medicine 2008;148(9):637-46.
  40. Goodson NJ, Brookhart MA, Symmons DP, Silman AJ and Solomon DH. Non-Steroidal Anti-Inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: Results from a primary care based inception cohort of patients. Annals of the Rheumatic Diseases 2008;68(3):367-72.
  41. Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK and Shrank WH. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. Journal of the American Medical Association 2008; 300(21):2514-26.
  42. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S and Decramer M; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine 2008;359:1543-54.
  43. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC and Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine 2007;356:775-89.
  44. Bounthavong M and Okamoto MP. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia. Journal of Evaluation in Clinical Practice 2007;13(3):453-60.
  45. Brooks N, Trent C, Raetzsche C, Flurkey K, Boysen G, Perfetti M, Jeong Y, Klebanov S, Patel K, Khodush V, Kupper L, Carling D, Swenberg J, Harrison D and Combs T. Low utilization of circulating glucose after food withdrawal in Snell dwarf mice. Journal of Biological Chemistry November 2007;282(48):35069-77.
  46. Schneeweiss S, Setoguchi S, Brookhart MA, Dormuth C and Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. Canadian Medical Association Journal 2007;176(5):627-32.
  47. Wang PS, Schneeweiss S, Setoguchi S, Patrick A, Avorn J, Mogun H, Choudhry NK and Brookhart MA. Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications. Journal of Clinical Psychopharmacology 2007;27(6):707-10.
  48. Mclay RN and HO J. Post-traumatic stress disorder-like symptoms after treatment with acetylcholinesterase inhibitors. Journal of Neuropsychiatry & Clinical Neurosciences 2007;19(1):92-3.
  49. Hornby TG, Schmit BD and Theiss RD. Serotonergic modulation of motor function in human spinal cord injury. Society for Neuroscience, Atlanta, GA, 2006:146.20.
  50. O'Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA, Kalberg CJ and Knobil K. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006;130:647-56.
  51. Plowman BK, Boggie DT, Morreale AP, Schaefer MG, Delattre ML and Chan H. Sleep attacks in patients receiving dopamine-receptor agonists. American Journal of Health-System Pharmacy 2005;62(5):537-40.
  52. Hornby TG, Heckman CJ, Harvey R and Rymer WZ. Changes in voluntary torque and electromyographic activity following oral baclofen. Muscle and Nerve 2004;30:784-95.
  53. Boggie D, DeLattre M, Schaefer M and Morreale A. Therapeutic interchange of rofecoxib and celecoxib with valdecoxib. American Journal of Health-System Pharmacy 2004;61(13):1391-4.
  54. Boggie D, Delattre M, Schaefer M, Morreale A and Plowman B. Accuracy of splitting unscored valdecoxib tablets. American Journal of Health-System Pharmacy 2004;61(14):1482-3.
  55. Burk M, Morreale A and Cunningham F. Conversion from troglitazone to rosiglitazone or pioglitazone in the VA: A multicenter DUE. Formulary 2004;39.
  56. Grillon C, Cordova J, Morgan III CA, Charney DS and Davis M. Effects of the beta-blocker propranolol on cued and contextual fear conditioning in humans. Psychopharmacology 2004;175(3):342-52.
  57. Rasmusson AM, Vasek J, Lipschitz DS,Vojvoda D, Mustone ME, Shi Q, Gudmundsen G, Morgan CA, Wolfe J and Charney DS. An increased capacity for adrenal DHEA release is associated with decreased avoidance and negative mood symptoms in women with PTSD. Neuropsychopharmacology 2004;29(8):1546-57.
  58. Tran F, Boggie DT, Delattre ML, Schaefer MG, Morreale AP and Plowman BK. Therapeutic interchange involving replacement of rofecoxib or celecoxib with valdecoxib. American Journal of Health-System Pharmacy 2004;61(13):1391-4.
  59. Decramer M, Celli B, Tashkin D, Pawels R, Burkhart D, Cassino C and Kesten S. Clinical trial design considerations in assessing long-term functional impacts of Tiotropium. COPD 2004;1:303-12.
  60. Castaldo R, Celli B, Gomez F, LaValle N, Souhrada J and Hanrahan J. A comparison of 5-Days courses of Dirithromycin and Azithromycin in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clinical Therapeutics 2003;25:1-15.
  61. Grillon C, Cordova J, Levine L and Morgan III CA. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology 2003;168(4):446-54.
  62. Le G, Schaefer M, Plowman B, Morreale A, Delattre M, Okino L and Felico L. Assessment of potential digoxin-rabeprazole interaction after formulary conversion of proton-pump inhibitors. American Journal of Health-Systems Pharmacy 2003;60(13):1343-5.
  63. Morgan III CA, Southwick SM and Krystal JH. Toward a pharmacology of acute stress disorders. Biological Psychiatry 2003;53(9):834-43.
  64. Morreale A. Accuracy of splitting unscored valdecoxib tablets versus scored controls. ACCP Meeting, Palm Springs, CA, April 2003.
  65. Schaefer M, Plowman B, Morreale A and Egan M. Interaction of Rofecoxib and Celecoxib with-Warfarin. American Journal of Health-Systems Pharmacy 2003; 60(13):1319-23.
  66. Baas JMP, Grillon C, Boecker KBE, Brack AA, Morgan III CA, Kenemans JL and Verbaten MN. Benzodiazepines have no effect on fear-potentiated startle in humans. Psychopharmacology 2002;161(3):233-47.
  67. Morreale A. Formulary conversion of proton pump inhibitors: Monitoring for potential drug interaction. Seminar sponsored by Community Health Services Pharmacists, Anaheim, CA, 2002.
  68. Ito M, Lin J, Morreale A, Marcus D, Shabeti R, Dresselhaus T and Henry R. Effect of Pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol. American Journal of Health-Systems Pharmacy 2001;58(18):1680.
  69. Stine SM, Grillon CG, Morgan III CA, Kosten TR, Charney DS and Krystal JH. Methadone patients exhibit increased startle and cortisol response after intravenous yohimbine. Psychopharmacology 2001;154(3):274-81.
  70. Gonzales R. Buprenorphine: medical consequences of liquid and tablet formulations. Western Psychological Conference. Portland, Oregon, May 2000.
  71. Krystal JH, Webb E, Grillon C, Cooney N, Casa L, Morgan III CA, Southwick SM, Davis M and Charney DS. Evidence of acoustic startle hyper-reflexia in recently detoxified alcoholics: Modulation by yohimbine and m-chlorophenylpiperazine (mCPP). Psychopharmacology 1997;131:207-15.
  72. Dricks M, Craven D, Celli B, Manning M, Burke R, Garvin G, Kunches L and McCabe W. Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers: The role of Gastric Colonization. New England Journal of Medicine 1987;317:1376-82.